Oxonica Limited, headquartered in Haddenham, Buckinghamshire, UK, is an advanced materials business specializing in the licensing of patents related to nanomaterials. The company primarily focuses on preserving cash resources to ensure ongoing operations and to support capital returns to shareholders. Oxonica's revenue is derived from two main sources: the release of deferred income from a 2008 agreement with BD (formerly Becton, Dickinson) related to bio diagnostic products, and royalties from a licensing agreement with Croda. The company is highly dependent on these licensing agreements for its revenue stream. While the agreement with Croda guarantees minimum royalty payments through the end of 2019, the BD agreement has yet to generate significant revenues and is subject to a lengthy product development and evaluation process. Oxonica aims to manage its cost base efficiently and return surplus capital to shareholders in a tax-efficient manner.

Keywords: nanomaterials, licensing, patents, royalties, bio diagnostics, Croda, BD, capital returns, cost management, advanced materials.